Skip to main content
For Healthcare Professionals
Banner-Background

OVERALL POPULATION

JASCAYD® demonstrated a statistically significant reduction in FVC decline at week 521

PPF-FVC-Decline-Overall-18mg
PPF-FVC-Decline-Overall-18mg

FVC, forced vital capacity.

relativ-reduction_2
relativ-reduction_2

FVC, forced vital capacity.

Quicklinks

JASCAYD® 18 mg demonstrated an early and sustained reduction in FVC decline that continued to diverge2

jascayd-18-mg-demonstrated-an-early-and-sustained-reduction
jascayd-18-mg-demonstrated-an-early-and-sustained-reduction

FVC DECLINE BY ILD

JASCAYD® 18 mg demonstrated a consistent reduction of FVC decline regardless of underlying condition at week 521,3

fvc-decline_1
fvc-decline_1

*Numerical reduction in FVC decline was demonstrated with JASCAYD® 18 mg +/- nintedanib across all underlying autoimmune ILDs besides "other ILDs". "Other ILDs" demonstrated nominal statistical significance.3

ILD, interstitial lung disease.

WITHOUT NINTEDANIB

JASCAYD® 18 mg without nintedanib demonstrated a reduction in FVC decline at week 521

These results were consistent with the overall trial population1

fvc-reduction
fvc-reduction

WITH NINTEDANIB

JASCAYD® 18 mg demonstrated a reduction in FVC decline for those on background nintedanib at week 521

These results were consistent with the overall trial population1

reduction-in-fvc
reduction-in-fvc

JASCAYD® was proven to preserve lung function by reducing FVC decline1

Quicklinks
References

  1. Maher TM, Assassi S, Azuma A, et al. FIBRONEER-ILD Trial Investigators. Nerandomilast in patients with progressive pulmonary fibrosis. N Engl J Med. 2025;392(22):2203-2214.

  2. Wijsenbeek MS, Assassi S, Azuma A, et al. Effect of nerandomilast on clinical outcomes in patients with progressive pulmonary fibrosis (PPF): results from the final database lock of the FIBRONEER-ILD trial. 2025. Presented at: European Respiratory Society (ERS) International Congress; September 2025; Vienna, Austria. Poster available from: https://www.globalmedcomms.com/respiratory/ERS2025/Wijsenbeek1.

  3. JASCAYD® UAE Local SmPC; May 2026.

MLR ID: PC-AE-102895
Expiry Date: 10/05/2028